Anyone affected by cancer after taking Byetta is encouraged to speak with a lawyer about their legal options.
Los Angeles, CA (PRWEB) June 18, 2013
The diabetes drug safety center at DrugRisk.com is announcing updated information for patients taking the medication Byetta. The FDA met with drug makers last week to decide additional safety studies of the drug after reports linking it to pancreatic cancer*.
The goal of DrugRisk is to improve the safety of patients taking popular prescription drugs by providing the latest warnings, recalls, studies and legal news. Visitors can see if others are experiencing similar side effects and decide if they need legal advice.
Byetta is a twice-daily injectable medication released in 2005 to help those with type-2 diabetes control blood sugar. Last year the drug had sales of over $300 million for manufacturer Bristol-Myers Squibb**.
The resource center added a 2011 study from the University of California at Los Angeles, indicating Byetta could increase the risk of pancreatic cancer by 290% and thyroid cancer by 473%***.
The Journal for the American Medical Association also recently warned that drugs like Byetta can double the risk of pancreatitis, a major risk factor for pancreatic cancer****.
Now, DrugRisk has learned that the FDA met last week with diabetes drug manufacturers to discuss how to approach new studies aimed at identifying Byetta cancer risks after receiving reports that some patients who died showed signs of early pancreatic cancer cells*.
Due to the number of patients filing a Byetta lawsuit alleging cancer, lawyers have asked that cases be consolidated to a special federal multi-district court in California. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, United States Judicial Panel on Multidistrict Litigation).
Anyone affected by cancer after taking Byetta is encouraged to speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers already handling Byetta lawsuits.
*Bloomberg, 6/12/13; bloomberg.com/news/2013-06-12/merck-joins-novo-to-reassure-safetynof-diabetes-drugs.html
**Bloomberg, 2/25/13; bloomberg.com/news/2013-02-25/merck-bristol-diabetes-drugs-linked-to-pancreatitis-risk.html
***Gastroenterology, July 2011; ctsi.ucla.edu/education/files/publicview/training/docs/FDA-analysis.pdf
****JAMA Internal Medicine, 2/25/13; archinte.jamanetwork.com/article.aspx?articleid=1656537